{"id":11140,"date":"2026-07-06T15:34:02","date_gmt":"2026-07-06T13:34:02","guid":{"rendered":"https:\/\/www.iqac.csic.es\/proyecto\/photoswitchable-beta-blockers-for-optimal-control-of-intraocular-pressure-in-glaucoma-patients\/"},"modified":"2026-07-06T15:34:02","modified_gmt":"2026-07-06T13:34:02","slug":"photoswitchable-beta-blockers-for-optimal-control-of-intraocular-pressure-in-glaucoma-patients","status":"publish","type":"proyecto","link":"https:\/\/www.iqac.csic.es\/en\/project\/photoswitchable-beta-blockers-for-optimal-control-of-intraocular-pressure-in-glaucoma-patients\/","title":{"rendered":"Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients"},"content":{"rendered":"<p>Glaucoma is one of the leading causes of irreversible blindness. Its usual treatment relies on eye drops that can cause systemic side effects due to drug diffusion throughout the body. Furthermore, these therapies have limitations in efficacy and low adherence. The GLAUxIS project proposes an innovative solution based on photoswitchable beta-blockers activated by visible light directly in the eye. This strategy allows for precise control of drug activity in space and time, achieving a reduction in intraocular pressure and avoiding adverse effects in other organs. Through the GLAUxIS project, we aim to offer society a glaucoma treatment using safer, more effective, and patient-centered therapies.     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Current glaucoma treatments present significant limitations due to side effects, low efficacy, and poor patient adherence. Within the framework of GLAUxIS, we are developing visible light-activated drugs that allow for precise, safe, and localized control of intraocular pressure. <\/p>\n","protected":false},"featured_media":11141,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[174,173],"enfermedad":[214],"framework":[131],"linea-de-investigacion":[172,163],"class_list":["post-11140","proyecto","type-proyecto","status-publish","has-post-thumbnail","hentry","tag-drug-discovery","tag-medicinal-chemistry","enfermedad-ophthalmology","framework-plan-estatal-peicti","linea-de-investigacion-treat","linea-de-investigacion-understand","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"og:description\" content=\"Current glaucoma treatments present significant limitations due to side effects, low efficacy, and poor patient adherence. Within the framework of GLAUxIS, we are developing visible light-activated drugs that allow for precise, safe, and localized control of intraocular pressure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/\" \/>\n<meta property=\"og:site_name\" content=\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/iqac.csic.es\/\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/glau-x-is.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"1335\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@IQAC_CSIC\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/proyecto\\\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/proyecto\\\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\\\/\",\"name\":\"Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/proyecto\\\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/proyecto\\\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/glau-x-is.jpg\",\"datePublished\":\"2026-07-06T13:34:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/proyecto\\\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.iqac.csic.es\\\/proyecto\\\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/proyecto\\\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/glau-x-is.jpg\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/glau-x-is.jpg\",\"width\":2000,\"height\":1335,\"caption\":\"Ilustraci\u00f3n art\u00edstica de un ojo que representa betabloqueantes fotoconmutables para controlar la presi\u00f3n intraocular en pacientes con glaucoma.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/proyecto\\\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.iqac.csic.es\\\/en\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"description\":\"Chemistry for a better life\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\"},\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.iqac.csic.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"width\":512,\"height\":512,\"caption\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/iqac.csic.es\\\/\",\"https:\\\/\\\/x.com\\\/IQAC_CSIC\",\"https:\\\/\\\/www.instagram.com\\\/iqac_csic\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC1JXTOe3-s8UnYu_A6-SI3A\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/iqac-csic\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/","og_locale":"en_US","og_type":"article","og_title":"Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","og_description":"Current glaucoma treatments present significant limitations due to side effects, low efficacy, and poor patient adherence. Within the framework of GLAUxIS, we are developing visible light-activated drugs that allow for precise, safe, and localized control of intraocular pressure.","og_url":"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/","og_site_name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","article_publisher":"https:\/\/www.facebook.com\/iqac.csic.es\/","og_image":[{"width":2000,"height":1335,"url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/glau-x-is.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@IQAC_CSIC","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/","url":"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/","name":"Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","isPartOf":{"@id":"https:\/\/www.iqac.csic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/#primaryimage"},"image":{"@id":"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/glau-x-is.jpg","datePublished":"2026-07-06T13:34:02+00:00","breadcrumb":{"@id":"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/#primaryimage","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/glau-x-is.jpg","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/glau-x-is.jpg","width":2000,"height":1335,"caption":"Ilustraci\u00f3n art\u00edstica de un ojo que representa betabloqueantes fotoconmutables para controlar la presi\u00f3n intraocular en pacientes con glaucoma."},{"@type":"BreadcrumbList","@id":"https:\/\/www.iqac.csic.es\/proyecto\/betabloqueantes-fotoconmutables-para-un-control-optimo-de-la-presion-intraocular-en-pacientes-con-glaucoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.iqac.csic.es\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Photoswitchable beta-blockers for optimal control of intraocular pressure in glaucoma patients"}]},{"@type":"WebSite","@id":"https:\/\/www.iqac.csic.es\/#website","url":"https:\/\/www.iqac.csic.es\/","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","description":"Chemistry for a better life","publisher":{"@id":"https:\/\/www.iqac.csic.es\/#organization"},"alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.iqac.csic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.iqac.csic.es\/#organization","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","url":"https:\/\/www.iqac.csic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","width":512,"height":512,"caption":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC"},"image":{"@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/iqac.csic.es\/","https:\/\/x.com\/IQAC_CSIC","https:\/\/www.instagram.com\/iqac_csic","https:\/\/www.youtube.com\/channel\/UC1JXTOe3-s8UnYu_A6-SI3A","https:\/\/www.linkedin.com\/company\/iqac-csic\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/proyecto\/11140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/proyecto"}],"about":[{"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/types\/proyecto"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/media\/11141"}],"wp:attachment":[{"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/media?parent=11140"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/tags?post=11140"},{"taxonomy":"enfermedad","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/enfermedad?post=11140"},{"taxonomy":"framework","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/framework?post=11140"},{"taxonomy":"linea-de-investigacion","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/en\/wp-json\/wp\/v2\/linea-de-investigacion?post=11140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}